Advanced Therapies Conference to Include Gene Modified Therapy Track – Exacis Biotherapeutics CEO to Participate in Panel Discussion

Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will serve on a panel exploring the difference between autologous and allogeneic stem cell therapies during the Advanced Therapies Conference. The panel, “Autologous vs Allogeneic,” is part of the Gene Modified Cell Therapy track for conference attendees. Exacis is a cell therapy company using mRNA to reprogram somatic cells to iPSCs and then using a proprietary mRNA based gene editing platform to engineer the cells before differentiation into immune effector (T and NK) cells for cancer applications. Dr. Fiore will share his knowledge of the research and developments in the rapidly growing cell therapy field.

“The currently approved autologous cell therapies are making a big difference for patients, although they are limited in their availability due to multiple factors. Allogeneic therapies hold promise to overcome these accessibility barriers,” said Dr. Fiore. “Exacis and others are working to develop lower cost, off-the-shelf cell therapies in order to allow many more patients to benefit from these lifesaving treatments.”

The panel will take place at 12:20 pm GMT on Wednesday, May 25.

The Advanced Therapies Conference will be held May 24-25, 2022, in London. Meeting attendees will explore important topics in the Advanced Therapy Medicinal Products (ATMP) space and the conference will showcase the latest technologies and advancements in the industry. The event will bring together 1,500 attendees from across the ATMP industry from pharma, biotech, research, regulatory bodies, HTAs investment and start-ups. The agenda includes 8 focused topic tracks, 300 speakers, and 100 sponsors and exhibitors.

About Exacis Biotherapeutics

Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.

Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

Contact Exacis Biotherapeutics for further information and media: 

Exacis Biotherapeutics